View More
In this commentary, an expert explains how high-dose IL-2 continues to have a role in the management of resistant or progressive melanoma and discusses evolving ways to incorporate IL-2 therapy into melanoma care.
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.